Back to Search Start Over

Lixte plans Nasdaq uplisting to accelerate blood cancer trial.

Authors :
Taylor, Nick Paul
Source :
FierceBiotech; 9/4/2020, pN.PAG-N.PAG, 1p
Publication Year :
2020

Abstract

OTC-listed Lixte Biotechnology has filed to uplist to Nasdaq, raising $11 million in the process. The uplisting comes as Lixte seeks to accelerate enrollment in a phase 1b/2 myelodysplastic syndrome that is lagging behind expectations. [ABSTRACT FROM AUTHOR]

Subjects

Subjects :
HEMATOLOGIC malignancies
NASDAQ composite index
MYELODYSPLASTIC syndromes

Details

Language :
English
Database :
Complementary Index
Journal :
FierceBiotech
Publication Type :
Periodical
Accession number :
145534809

Tools

Authors Abstract Subjects Details